Navigation Links
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Date:2/7/2008

d HIV-1 strains resistant to a NNRTI and other ARV agents.

This indication is based on Week 24 analyses from two randomized, double- blind, placebo-controlled trials of INTELENCE. Both studies were conducted in clinically advanced, three-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults.

The following points should be considered when initiating therapy with INTELENCE:

-- Treatment history and, when available, resistance testing, should guide

the use of INTELENCE.

-- The use of other active antiretroviral agents with INTELENCE is

associated with an increased likelihood of treatment response.

-- In patients who have experienced virologic failure on an

NNRTI-containing regimen, do not use INTELENCE in combination with

only N[t]RTIs.

-- The risks and benefits of INTELENCE have not been established in

pediatric patients or in treatment-nave adult patients.

DUET-1 and -2 Study Design

The DUET-1 and -2 studies, identical in design but conducted in different regions, assessed the 24- and 48-week efficacy and safety of INTELENCE in combination with a BR in treatment-experienced adult HIV-1 patients with documented evidence of NNRTI and PI resistance. The primary endpoint was the proportion of patients who achieved a confirmed undetectable viral load (less than 50 copies/mL)

Patients with HIV-1 who were eligible for the DUET studies had a viral load of greater than 5,000 copies/mL while on a stable antiretroviral therapy regimen for at least eight weeks and had evidence of at least one NNRTI- resistance-associated mutation, either at screening or from prior resistance tests, as well as evidence of three or more primary PI mutations (D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, V82A/F/L/S/T, I84V, N88S, or L90M) at screening.

Participants in the DUET studies were randomized to receive INTELENCE 200 mg twice daily (599 patients) or pl
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
2. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
3. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
4. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
5. Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
6. Vanda Presents Phase III Iloperidone Efficacy Data
7. Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting
8. TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
10. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
11. Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... England, July 29, 2011 , ... The UK bioindustry has raised over $250m in financing ... any quarter for one year, and the second largest amount raised ... to the financing drought that saw three consecutive quarters below $100m ...
... Health Company (Nasdaq: FHCO ) today announced that ... operating results for the third quarter and first nine months ... Eastern Time (EDT).  The Company expects to report its operating ... other interested parties may participate in the conference call by ...
Cached Medicine Technology:UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 2UK Chalks Up $253 Million in Investment in Q2 2011: Oxford Cluster Takes the Largest Bite of the Apple 3The Female Health Company to Host Third Quarter Conference Call on Friday, August 5, 2011 2
(Date:7/10/2014)... Texas (July 10, 2014) Men who experience hot ... they may find relief from their silent suffering ... according to findings from a Baylor University case study., ... man who had uncontrolled hot flashes following prostate cancer ... flashes but also an impressive improvement in sleep quality, ...
(Date:7/9/2014)... -- The World Health Organization recommends that youth participate ... vigorous physical activity (MVPA) each day. Studies have ... school hours. Therefore, it stands to reason that ... In a new study scheduled for publication in ... time spent outdoors after school was positively associated with ...
(Date:7/9/2014)... July 10, 2014 For the first time, researchers ... Aboriginal population in Canada uses health care. A new ... to clearly demonstrate the unique challenges faced by urban ... St. Michael,s Hospital. , The findings, published today ... urban First Nations individuals and the general population. , ...
(Date:7/9/2014)... of Medicine at the University of Pennsylvania in collaboration ... $8 million grant from the National Cancer Institute (NCI) ... in patients with malignant pleural mesothelioma, a rare, aggressive ... the lining of the lungs and is caused almost ... a clinical trial and additional studies looking at the ...
(Date:7/9/2014)... types of cancer sends the protein factories in our ... uncontrolled growth, new research suggests. , Scientists at The ... responsible for ratcheting up activity of the endoplasmic reticulum ... blocks cancer cells need to keep growing. , A ... the flow of messages to the endoplasmic reticulum telling ...
Breaking Medicine News(10 mins):Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2
... the current standard of care to treat opioid-dependent ... findings from an international team led by Johns Hopkins ... the New England Journal of Medicine . ... to counter heroin and/or prescription opioid addiction were likely ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Dec. 9 ... on a new trick for weight loss: To eat less ... it up beforehand. Repeatedly imagining the consumption of a ... lead researcher Carey Morewedge, an assistant professor of social and ...
... of Cincinnati (UC) and Massachusetts General Hospital have ... may not be as beneficial to some patients ... findings were published online this week ahead of ... and Outcomes . Warfarin is commonly ...
... A genetic mutation associated with an inherited form of Lou ... lateral sclerosis (ALS) -- has been identified by an international ... are hereditary. In their study, the team used a ... the mutation in the valosin-containing protein (VCP) gene, which has ...
... (HealthDay News) -- Only 50 percent of women over age ... screen for breast cancer, even if they have insurance to ... a database of more than 12 million people to review ... the women included in the study had either employer-provided insurance ...
... of melanoma tumors by targeting the MIC-1 protein that ... better treatment of this invasive and deadly cancer, according ... Foreman Foundation Research Laboratory. , "Preventing vessels from developing ... growing," said lead author Gavin Robertson, Ph.D., professor of ...
Cached Medicine News:Health News:Buprenorphine is better than methadone for opioid dependence in pregnant women, study shows 2Health News:Mental Imagery a New Weight-Loss Tool? 2Health News:Mental Imagery a New Weight-Loss Tool? 3Health News:Blood-thinning treatment standards changing for heart patients, new research shows 2Health News:Blood-thinning treatment standards changing for heart patients, new research shows 3Health News:Only Half of Women Over 40 Get Annual Mammograms 2Health News:Protein targeted to stop melanoma tumor growth 2
... for the mid- to high-volume lab, the ... can reduce time-consuming manual tasks by as ... performs random access, STAT, HCFA panels and ... including Stat chemistries, General chemistries, TDMs, DATs, ...
... It takes powerful technology to ... safety, and still lower costs. ... LX20 PRO, offering features that ... any other chemistry analyzer, including ...
... This user-friendly instrument ... Plasma Protein analyzer for ... It is a well ... reliable results for a ...
For Detection of Bile Component in Reflux Disease...
Medicine Products: